Nutriband Past Earnings Performance
Past criteria checks 0/6
Nutriband's earnings have been declining at an average annual rate of -19.2%, while the Pharmaceuticals industry saw earnings growing at 0.5% annually. Revenues have been growing at an average rate of 37.5% per year.
Key information
-19.2%
Earnings growth rate
-12.7%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 37.5% |
Return on equity | -85.2% |
Net Margin | -263.0% |
Last Earnings Update | 31 Jan 2024 |
Recent past performance updates
Recent updates
Is Nutriband (NASDAQ:NTRB) A Risky Investment?
Mar 31Is Nutriband (NASDAQ:NTRB) Weighed On By Its Debt Load?
Sep 13Nutriband GAAP EPS of -$0.12, revenue of $0.5M
Sep 08Nutriband opens a new branch in Ecuador with plans to expand into the South American market
Jul 22Nutriband: Advancing Transdermal Delivery Of Injectable Drugs
Nov 01Does Nutriband (NASDAQ:NTRB) Have A Healthy Balance Sheet?
Oct 06Revenue & Expenses BreakdownBeta
How Nutriband makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Jan 24 | 2 | -5 | 4 | 2 |
31 Oct 23 | 2 | -5 | 4 | 2 |
31 Jul 23 | 2 | -5 | 4 | 1 |
30 Apr 23 | 2 | -5 | 4 | 1 |
31 Jan 23 | 2 | -4 | 4 | 1 |
31 Oct 22 | 2 | -7 | 4 | 1 |
31 Jul 22 | 2 | -7 | 5 | 1 |
30 Apr 22 | 1 | -7 | 4 | 1 |
31 Jan 22 | 1 | -6 | 4 | 0 |
31 Oct 21 | 1 | -5 | 5 | 0 |
31 Jul 21 | 1 | -3 | 4 | 0 |
30 Apr 21 | 1 | -3 | 3 | 0 |
31 Jan 21 | 1 | -3 | 3 | 0 |
31 Oct 20 | 1 | -2 | 1 | 0 |
31 Jul 20 | 0 | -2 | 1 | 0 |
30 Apr 20 | 0 | -3 | 1 | 0 |
31 Jan 20 | 0 | -3 | 2 | 0 |
31 Oct 19 | 0 | -2 | 2 | 0 |
31 Jul 19 | 1 | -2 | 2 | 0 |
30 Apr 19 | 0 | -3 | 3 | 0 |
31 Jan 19 | 0 | -3 | 3 | 0 |
31 Oct 18 | 0 | -5 | 3 | 0 |
31 Jul 18 | 0 | -5 | 2 | 0 |
30 Apr 18 | 0 | -3 | 1 | 0 |
31 Jan 18 | 0 | -3 | 0 | 0 |
31 Oct 17 | 0 | 0 | 0 | 0 |
31 Jul 17 | 0 | 0 | 0 | 0 |
30 Apr 17 | 0 | 0 | 0 | 0 |
31 Jan 17 | 0 | 0 | 0 | 0 |
Quality Earnings: NTRB is currently unprofitable.
Growing Profit Margin: NTRB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NTRB is unprofitable, and losses have increased over the past 5 years at a rate of 19.2% per year.
Accelerating Growth: Unable to compare NTRB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NTRB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.5%).
Return on Equity
High ROE: NTRB has a negative Return on Equity (-85.2%), as it is currently unprofitable.